Congenica is at the forefront of integrating genomics into healthcare. The company has developed a platform for utilizing patient-derived genomics data to analyze and interpret genetically inherited diseases by combining patients’ genetic and phenotypic data. Congenica’s platform Sapientia™ is currently being used by hospitals and clinics, diagnostic labs, and pharmaceutical companies, including Great Ormond Street Hospital, London, UniteGen, China and UCB Pharma.
Its nomination was based on its Series B financing round, which had its first close at £8m ($10m) in February 2017 with existing investors Cambridge Innovation Capital plc, Amadeus Capital Partners as well as new investor, Parkwalk Advisors. It then successfully finalized the round in April with additional investments from China-based BGI Genomics (BGI), a recognized global leader in genomics, Healthlink Capital (Healthlink), another well-established China-based life-science investor and Future Planet Capital, a UK-based global innovation fund. The investment will support the international commercial roll-out of Sapientia, the expansion of customer support as well as further product development and innovation. The Biotech and Money Awards celebrate funding, finance and investment successes over the past 12 months across the British Life Sciences sector. Winners of each category are determined 50% based on online voting (can be done here) and 50% on a live voting session during the Awards dinner, which will be held on 14 September in London. Further details of the Biotech and Money event: Assembly and Awards Gala Dinner Ends Background Information About Congenica: Congenica is a world-leading developer of genome-based discovery and diagnostic technologies, and has developed the Sapientia genome analysis technology platform that facilitates clinical and R&D decision-making worldwide. A private company, Congenica is backed by leading life science investors including Cambridge Innovation Capital, Amadeus Capital Partners, Parkwalk Advisors, a member firm of IP Group plc, BGI Genomics, Healthlink Capital and Future Planet Capital. Find out more about Congenica at www.congenica.com or follow @Congenica. About Sapientia™: Sapientia is a clinical genome analysis software platform that analyzes genome-scale DNA data to produce a comprehensive diagnostic report that can be linked to patients’ symptoms, supporting clinical decision-making about rare genetic disease. The platform is based on pioneering research from the UK’s Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories, and its underlying technology has been validated by leading independent institutes and clinicians, including Genomics England Ltd. Sapientia is also being used in the advancement of personalised medicine by the global pharmaceutical industry to create disease registries, identify patient populations for clinical studies, and support the discovery of novel drug targets and biomarkers. About Biotech and Money Awards 2017 Biotech and Money Assembly and Awards is a 250 person Gala Dinner celebrating the UK’s funding, finance and investment successes in the sector over the last 12 months. Leading lights and emerging stars, C-suite executives, impactful investors and powerful KOLs in the sector will be celebrating at one of London’s finest banqueting halls; Merchant Taylors Hall on 14th September 2017, from 6pm-11pm. For more information, please visit the website: http://www.biotechandmoney.com/gala-dinner
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
AuthorRare Revolution Editor Archives
July 2021
Categories |
RSS Feed